Interdicting metabolic disease at the level of NAD+ biosynthesis and/or hepatocyte glucose transport are proximal targets that may leverage the broader effects of hepatocyte NAMPT activation against aging, obesity, and other fasting-responsive diseases. The gene discussed is NAMPT; the disease is obesity due to melanocortin 4 receptor deficiency.